US EditionGlobal analysis shows widespread eligibility for GLP-1 weight management drugs
Study shows 27% of adults globally qualify for GLP-1 drugs, with four-fifths living in low- and middle-income countries, highlighting a major public health challenge.
5 Articles
5 Articles
Global analysis shows widespread eligibility for GLP-1 weight management drugs
The worldwide prevalence of obesity has more than doubled in the last three decades, bringing with it an increase in weight-related diseases like diabetes, cardiovascular disease, and cancers.
About a quarter of the world's adult population could benefit from the new drugs that have revolutionized the treatment of obesity, the famous GLP-1-semaglutide (Ozempic for diabetes, Wegovy for obesity) and lyraglutide (Saxenda for obesity)-. This is supported by a research published in 'The Lancet Diabetes & Endocrinology ' which proposes to facilitate access to these drugs to address this public health crisis.The global prevalence of obesity …
More than a quarter of adults worldwide could benefit from GLP-1 medications for weight loss, study finds
The worldwide prevalence of obesity has more than doubled in the last three decades, bringing with it an increase in weight-related diseases like diabetes, cardiovascular disease, and cancers. This public health crisis strains global health care systems and economies, but a new study co-led by investigators from Mass General Brigham could inform strategic programs to make GLP-1 medications part of the solution.
Global study finds broad eligibility for GLP-1 drugs
The prevalence of obesity has more than doubled globally over the past thirty years, leading to an increase in related diseases such as diabetes, cardiovascular conditions, and certain cancers. This burgeoning public health crisis places a significant strain on healthcare systems and economies worldwide. A new study, co-led by researchers from Mass General Brigham, suggests that integrating GLP-1 medications into treatment strategies could offer…
Racial Disparities in GLP-1 Prescriptions for Diabetes Treatment
It may seem that glucagon-like peptide-1 receptor agonists (GLP-1s) are everywhere these days. But these medications aren’t always easy to come by. And, it turns out, whether you’re prescribed one may partly depend on your racial background. GLP-1s can greatly help with regulating blood sugar and managing chronic conditions such as type 2 diabetes and obesity. But new research suggests Black and Latino people are less likely than white people to…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
